Neuropeptide Y

DRUG4 trials

Sponsors

James Murrough, Vanderbilt University, New York Medical College, University of Texas Southwestern Medical Center

Conditions

HypertensionObesityPosttraumatic Stress DisorderStress Disorders, Post-TraumaticStress Disorders, Traumatic, AcuteType 2 Diabetes Mellitus

Early Phase 1

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

RecruitingNCT04838678

University of Texas Southwestern Medical CenterHypertension, Obesity

Start: 2021-07-18End: 2026-08-31Target: 100Updated: 2025-08-24

Phase 1

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

CompletedNCT01533519

James MurroughPosttraumatic Stress Disorder

Start: 2012-12-31End: 2016-01-31Updated: 2016-04-14

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

New York Medical CollegeStress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute

Start: 2019-11-01End: 2022-11-01Target: 117Updated: 2019-08-28

Phase 4

Effect of DPP4 Inhibition on Vasoconstriction

CompletedNCT02639637

Vanderbilt UniversityType 2 Diabetes Mellitus

Start: 2015-12-31End: 2017-09-30Updated: 2018-08-27

Related Papers

A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder

The International Journal of Neuropsychopharmacology2017-11-1776 citations